Form 4: Centessa Pharmaceuticals PLC: Director Ownership Changes

Francesco De Rubertis, a Director at Centessa Pharmaceuticals PLC, reported changes in beneficial ownership of ordinary shares on June 24, 2026, following the company's acquisition by Eli Lilly and Company.

Summary

• Francesco De Rubertis, a Director of Centessa Pharmaceuticals PLC, has filed a Form 4 detailing changes in his beneficial ownership of the company's ordinary shares.
• The transactions occurred on June 24, 2026, coinciding with the effective time of the scheme of arrangement where Eli Lilly and Company, through its subsidiary LDH XV Corporation, acquired all outstanding ordinary shares of Centessa Pharmaceuticals.
• De Rubertis's ownership is reported across several entities, including Medicxi Ventures I LP, Medicxi Co-Invest I LP, Medicxi Growth I LP, Medicxi Growth Co-Invest I LP, Medicxi Secondary I LP, and Medicxi Secondary Co-Invest I LP.
• The filing indicates that De Rubertis disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the report is not an admission of such ownership for Section 16 purposes.
• A substitute Power of Attorney was also filed, appointing Raphael Deferiere as a substitute attorney-in-fact for various individuals, including Francesco De Rubertis, to execute SEC filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on ownership changes following a completed acquisition rather than new operational or financial performance.

Risks

• The filing itself does not present new risks but rather reports on a completed transaction (acquisition) and associated ownership changes.
• Potential future risks for shareholders would be related to the integration of Centessa's assets into Eli Lilly and the realization of contingent value rights (CVRs).

Future Outlook

The filing pertains to a completed acquisition and does not contain forward-looking statements or guidance from Centessa Pharmaceuticals itself. Future outlook is now tied to Eli Lilly and Company's strategic plans for the acquired assets.

Management Comments

• The Reporting Person disclaims Section 16 beneficial ownership of the securities held by [various Medicxi entities], except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the completion of a significant M&A event in the pharmaceutical sector, where a larger entity (Eli Lilly) acquires a smaller one (Centessa Pharmaceuticals). Such filings are standard procedure to report changes in beneficial ownership post-acquisition and are crucial for transparency regarding director and insider holdings.

Corporate Governance

Stakeholder Impact

• Shareholders: Former Centessa shareholders are now entitled to $38.00 in cash and a contingent value right (CVR) per share, with potential for additional payments based on milestones.
• Management/Directors: Reporting persons like Francesco De Rubertis are updating their beneficial ownership disclosures following the acquisition.
• Creditors: The acquisition by Eli Lilly, a financially strong entity, likely provides a stable outlook for Centessa's former creditors.

Next Steps

• Integration of Centessa Pharmaceuticals' assets and pipeline into Eli Lilly and Company's operations.
• Potential future payments to former Centessa shareholders related to Contingent Value Rights (CVRs) upon achievement of specified milestones.

Key Dates

Keywords

Centessa Pharmaceuticals, Form 4, Beneficial Ownership, Francesco De Rubertis, Eli Lilly and Company, Acquisition, Scheme of Arrangement, Ordinary Shares, SEC Filing, Director